Brad Frandsen, MD
Family Medicine · Port Orchard, WANPI 1700820966
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,339 of the $2,089 with a category attached, or 64.1%. Bayer accounts for 81.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $1,726 and has fallen 88.1% since, to $206 in 2025. Among family medicine clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $63.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$2K
- Pfizer$103
- Novo Nordisk$79
- Amgen$45
- Merck$43
- Lilly USA, LLC$40
- plus $87 from 5 others
Across 259 payments — averaging $6513.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1M
- Bavarian Nordic A/s$587K
- AstraZeneca$35K
- Gilead$23K
- AbbVie$13K
- Astrazeneca UK Limited$11K
- plus $6K from 1 others
What the payments were for
- Travel & lodging$1,33964%
- Food & beverage$71534%
- Education$352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 8 | $1,692 |
| Pfizer | 10 | $103 |
| Novo Nordisk | 3 | $79 |
| Amgen | 3 | $45 |
| Merck | 2 | $43 |
| Lilly USA, LLC | 2 | $40 |
| AbbVie | 1 | $34 |
| GSK | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $12 |
| AstraZeneca | 1 | $12 |
| Radius Health, Inc. | 1 | $11 |
How this compares
$2,089 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $125,250 |
| XareltoRivaroxaban | 59 | $73,511 |
| JardianceEmpagliflozin | 39 | $52,425 |
| EliquisApixaban | 32 | $44,914 |
| TrulicityDulaglutide | 11 | $27,296 |
| MounjaroTirzepatide | 13 | $18,364 |
| Atorvastatin Calcium | 665 | $6,733 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $4,528 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $4,066 |
| Irbesartan | 126 | $3,360 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $2,808 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,502 |
| Metoprolol Succinate | 140 | $2,303 |
| Candesartan Cilexetil | 17 | $2,240 |
| Gabapentin | 123 | $2,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $79 | $125,25093 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $40 | $45,66024 claims |
| PfizerEliquis | $103 | $44,91432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Port Orchard
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
- Cynthia CoteMaple Valley$66K
- Greg LedgerwoodBrewster$66K
- Daniel RivasBurien$50K
- Kent WalkerSumner$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.